Pharma Bio Operating Margin vs. Price To Sales

PBSV Stock  USD 0.55  0.06  9.84%   
Considering Pharma Bio's profitability and operating efficiency indicators, Pharma Bio Serv may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Pharma Bio's ability to earn profits and add value for shareholders.
For Pharma Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pharma Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pharma Bio Serv utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pharma Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pharma Bio Serv over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Please note, there is a significant difference between Pharma Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharma Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharma Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Pharma Bio Serv Price To Sales vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Pharma Bio's current stock value. Our valuation model uses many indicators to compare Pharma Bio value to that of its competitors to determine the firm's financial worth.
Pharma Bio Serv is regarded fourth in operating margin category among its peers. It is rated below average in price to sales category among its peers fabricating about  14.86  of Price To Sales per Operating Margin. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharma Bio's earnings, one of the primary drivers of an investment's value.

Pharma Price To Sales vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Pharma Bio

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.06 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Pharma Bio

P/S

 = 

MV Per Share

Revenue Per Share

 = 
0.90 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Pharma Price To Sales Comparison

Pharma Bio is currently under evaluation in price to sales category among its peers.

Pharma Bio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Pharma Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Pharma Bio will eventually generate negative long term returns. The profitability progress is the general direction of Pharma Bio's change in net profit over the period of time. It can combine multiple indicators of Pharma Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico. Pharma Bio operates under Health Information Services classification in the United States and is traded on OTC Exchange. It employs 190 people.

Pharma Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Pharma Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Pharma Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Pharma Bio's important profitability drivers and their relationship over time.

Use Pharma Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pharma Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pharma Bio will appreciate offsetting losses from the drop in the long position's value.

Pharma Bio Pair Trading

Pharma Bio Serv Pair Trading Analysis

The ability to find closely correlated positions to Pharma Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pharma Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pharma Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pharma Bio Serv to buy it.
The correlation of Pharma Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pharma Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pharma Bio Serv moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pharma Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Pharma Bio position

In addition to having Pharma Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Services Thematic Idea Now

Services
Services Theme
Companies involved in delivering services to business or consumers across different industries and sectors. The Services theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Services Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Pharma OTC Stock Analysis

When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.